Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Cash & Current Investments (2021 - 2025)

Valion Bio has reported Cash & Current Investments over the past 5 years, most recently at $12.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 602.5% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, up 602.5%, while the annual FY2025 figure was $12.6 million, 602.5% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $12.6 million at Valion Bio, up from $3.5 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $12.8 million in Q1 2021 and troughed at $700000.0 in Q1 2025.
  • A 5-year average of $5.4 million and a median of $3.6 million in 2022 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: tumbled 76.01% in 2023 and later soared 602.5% in 2025.
  • Year by year, Cash & Current Investments stood at $12.8 million in 2021, then plummeted by 72.51% to $3.5 million in 2022, then fell by 7.79% to $3.2 million in 2023, then plummeted by 44.5% to $1.8 million in 2024, then soared by 602.5% to $12.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for TIVC at $12.6 million in Q4 2025, $3.5 million in Q3 2025, and $975000.0 in Q2 2025.